ReviewCurrent opinion in chemical biology2010
The chemical biology of new drugs in the development for tuberculosis.
Review in Current opinion in chemical biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Indole-fused spirochromenes as potential anti-tubercular agents: design, synthesis and in vitro evaluation.Molecular diversity · 2021Article
- Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.Nature communications · 2018Article
- Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation.Molecular diversity · 2017Article
- Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.The Journal of antibiotics · 2015Article
- Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.Analytical biochemistry · 2014Article
- Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis.Biochemistry · 2014Article
- Bisubstrate Inhibitors of Biotin Protein Ligase inACS medicinal chemistry letters · 2013Article
- Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.Future microbiology · 2013Review
- Kinetics of IFN-gamma and TNF-alpha gene expression and their relationship with disease progression after infection with Mycobacterium tuberculosis in guinea pigs.Yonsei medical journal · 2013Article
- An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages.Antimicrobial agents and chemotherapy · 2012Article
- SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2012Article
- Identification and characterization of inhibitors of the aminoglycoside resistance acetyltransferase Eis from Mycobacterium tuberculosis.ChemMedChem · 2012Article
- Adenylating enzymes in Mycobacterium tuberculosis as drug targets.Current topics in medicinal chemistry · 2012Review
- Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.Antimicrobial agents and chemotherapy · 2011Article
- Mechanism-based inactivation by aromatization of the transaminase BioA involved in biotin biosynthesis in Mycobaterium tuberculosis.Journal of the American Chemical Society · 2011Article
- The progress made in determining the Mycobacterium tuberculosis structural proteome.Proteomics · 2011Review
- Potent inhibitors of a shikimate pathway enzyme from Mycobacterium tuberculosis: combining mechanism- and modeling-based design.The Journal of biological chemistry · 2011Article
- Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds.Microbiological researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With the worldwide emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (Mtb), there are serious concerns about the continued ability to contain this disease. We discuss the most promising new drugs in late-stage development that might be useful in treating MDR and XDR forms of the disease. These agents have novel mechanisms of action that are not targeted by the standard drugs used presently to treat susceptible strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.